Gabby's Training Example-Portuguese 2026-2027 Renewal Content packet

Portuguese 2026-2027 Renewal Content packet

Pdf Summary

This confidential APHON renewal package for pediatric chemotherapy and biotherapy providers outlines practice expectations and updates on emerging therapies, survivorship, and oncologic emergencies. Pediatric chemotherapy and biotherapy must be administered by registered nurses who complete APHON training; provider status is renewed every two years through an online examination. Employers are encouraged to provide annual training and clinical skills validation.<br /><br />The neuroblastoma section reviews its variable presentation, diagnostic approaches, and anti-GD2 immunotherapies. Dinutuximab is generally used as post-consolidation maintenance, while naxitamab is used for relapsed or refractory disease involving bone or bone marrow. Both can cause severe neuropathic pain and infusion reactions; key nursing priorities include pain control, close cardiovascular monitoring, and prompt recognition of capillary leak or other serious toxicities.<br /><br />The menin-inhibitor section describes revumenib and ziftomenib as targeted treatments for certain relapsed or refractory leukemias with KMT2A rearrangements or NPM1 mutations. Nurses should watch for differentiation syndrome, QT prolongation, cytopenias, infection, bleeding, and drug interactions, and support careful laboratory and ECG monitoring.<br /><br />The survivorship section emphasizes that improved survival brings substantial lifelong risks, including endocrine and cardiovascular problems, infertility, hearing loss, secondary cancers, and psychosocial effects. It discusses potential protective therapies and recommends individualized, ongoing follow-up, especially for adolescent and young adult survivors.<br /><br />Finally, the package reviews four pediatric oncologic emergencies: posterior reversible encephalopathy syndrome (PRES), tumor lysis syndrome, sinusoidal obstruction syndrome/veno-occlusive disease, and typhlitis. Early recognition of symptoms, vigilant monitoring, timely treatment, accurate documentation, and family education are central nursing responsibilities.

Keywords

pediatric chemotherapy

biotherapy providers

APHON renewal

neuroblastoma

dinutuximab

naxitamab

menin inhibitors

revumenib

survivorship

oncologic emergencies